Systemic Therapy for Metastatic Colorectal Cancer: Patterns of Chemotherapy and Biologic Therapy Use in US Medical Oncology Practice
- 1 November 2010
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Oncology Practice
- Vol. 6 (6) , 301-307
- https://doi.org/10.1200/jop.2010.000072
Abstract
The optimal combination and sequencing of new chemotherapies and biologic agents in the treatment of metastatic colorectal cancer are yet to be determined. This study examined the extent and pattern of use by line of treatment.Keywords
This publication has 12 references indexed in Scilit:
- Hidden Biases in an Observational Study of Bevacizumab Beyond ProgressionJournal of Clinical Oncology, 2009
- Bevacizumab Beyond First Progression Is Associated With Prolonged Overall Survival in Metastatic Colorectal Cancer: Results From a Large Observational Cohort Study (BRiTE)Journal of Clinical Oncology, 2008
- Optimal approach to potentially resectable liver metastases from colorectal cancerExpert Review of Anticancer Therapy, 2008
- The Continuum of Care: A Paradigm for the Management of Metastatic Colorectal CancerThe Oncologist, 2007
- Metastatic Colorectal CancerDrugs, 2007
- Therapy for Metastatic Colorectal CancerThe Oncologist, 2006
- Systemic Therapy for Metastatic Colorectal Cancer: Current Options, Current EvidenceJournal of Clinical Oncology, 2005
- Systemic Therapy for Colorectal CancerNew England Journal of Medicine, 2005
- Changes in liver surgery for colorectal cancer liver metastases under neoadjuvant treatment strategiesEuropean Surgery, 2004
- FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR StudyJournal of Clinical Oncology, 2004